Outcome of medical therapy, repeat intervention, and mitral valve surgery after failed MitraClip therapy.
Medical therapy
MitraClip failure
Repeat MitraClip therapy
Surgical revision
Journal
General thoracic and cardiovascular surgery
ISSN: 1863-6713
Titre abrégé: Gen Thorac Cardiovasc Surg
Pays: Japan
ID NLM: 101303952
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
23
03
2020
accepted:
16
10
2020
pubmed:
30
10
2020
medline:
24
4
2021
entrez:
29
10
2020
Statut:
ppublish
Résumé
Optimal treatment for residual mitral regurgitation (MR) after MitraClip failure is not clearly defined. We report our clinical experience and discuss treatment options. Between January 2013 and January 2018, 37 patients (75 ± 8.9 years, 46% male) were admitted for symptomatic MR (grade 3.1 ± 0.47) diagnosed after previous MitraClip therapy. Clinical outcome of these patients, who underwent medical therapy alone (n = 8, M-group), repeat MitraClip therapy (n = 8, reMC group), or mitral valve surgery (n = 21, S-group) for residual MR, were retrospectively analyzed. Thirty-day survival was 88% (M-group), 100% (reMC-group), and 76% (S-group). The rate of discharge to home was 88% in the reMC-group, better than 38% in the M-group (p = 0.051) and 19% in the S-group (p < 0.001). Perioperative non-survivors in the S-group had high surgical risk with median logistic EuroSCORE of 64.6% (interquartile range 57.4%-87.0%); all died from low cardiac output syndrome or multiple organ failure. The main MR pathologies resulted from leaflet tear and tethering in the M-group, tethering in the reMC-group, and degenerative valve and leaflet tear in the S-group. Kaplan-Meier analysis of overall survival at 1 year showed better outcome for patients in the reMC-group (50%, 95% CI 15.2-77.5%) and S-group (47.6%, 95% CI 25.7-66.7%), as compared to those in the M-group (12.5%, 95% CI 0.70-42.3%) (log-rank test p = 0.108 and p = 0.167, respectively). Medical therapy alone after failed MitraClip therapy resulted in poor 1-year prognosis. In patients without extremely high surgical risk, repeat MitraClip therapy, or surgical revision MIGHT BE CONSIDERED depending on valve pathology and cardiac comorbidities.
Identifiants
pubmed: 33118111
doi: 10.1007/s11748-020-01530-z
pii: 10.1007/s11748-020-01530-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
803-810Références
Feldman T, Foster E, Glower DD, Kar S, Rinaldi MJ, Fail PS, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011;364:1395–406.
doi: 10.1056/NEJMoa1009355
Feldman T, Kar S, Elmariah S, Smart SC, Trento A, Siegel RJ, et al. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: 5-year results of EVEREST II. J Am Coll Cardiol. 2015;66:2844–54.
doi: 10.1016/j.jacc.2015.10.018
Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018;379:2307–18.
doi: 10.1056/NEJMoa1806640
Sorajja P, Vemulapalli S, Feldman T, Mack M, Holmes DR Jr, Stebbins A. Outcomes with transcatheter mitral valve repair in the United States: An STS/ACC TVT registry report. J Am Coll Cardiol. 2017;70:2315–27.
doi: 10.1016/j.jacc.2017.09.015
Maisano F, Franzen O, Baldus S, Schäfer U, Hausleiter J, Butter C. Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multi-center, nonrandomized post-approval study of the MitraClip therapy in Europe. J Am Coll Cardiol. 2013;62:1052–61.
doi: 10.1016/j.jacc.2013.02.094
Geidel S, Wohlmuth P, Schmoeckel M. Survival prediction in patients undergoing open-heart mitral valve operation after previous failed mitraclip procedures. Ann Thorac Surg. 2016;101:952–8.
doi: 10.1016/j.athoracsur.2015.08.086
Kreidel F, Alessandrini H, Wohlmuth P, Schmoeckel M, Geidel S. Is surgical or catheter-based interventions an option after an unsuccessful mitral clip? Semin Thorac Cardiovasc Surg. 2018;30:152–7.
doi: 10.1053/j.semtcvs.2018.03.005
Kreidel F, Frerker C, Schlüter M, Alessandrini H, Thielsen T, Geidel S. Repeat MitraClip therapy for significant recurrent mitral regurgitation in high surgical risk patients: impact of loss of leaflet insertion. JACC Cardiovasc Interv. 2015;8:1480–9.
doi: 10.1016/j.jcin.2015.06.019
Gyoten T, Schenk S, Rochor K, Harnath A, Grimmig O, Just S, et al. Surgical revision of failed percutaneous edge-to-edge mitral valve repair: lessons learned. Interact Cardiovasc Thorac Surg. 2019;28:900–7.
doi: 10.1093/icvts/ivy227
Boekstegers P, Hausleiter J, Baldus S, et al. Interventionelle behandlung der mitralklappeninsuffizienz mit dem MitraClip®-verfahren: empfehlungen des arbeitskreises interventionelle mitralklappentherapie der arbeitsgemeinschaft interventionelle kardiologie (AGIK) der deutschen gesellschaft für kardi. Kardiologe. 2013;7:91–104.
doi: 10.1007/s12181-013-0492-5
Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J, et al. Angiotensin receptor neprilysin inhibition in heart failure with pre trial. JACC Heart Fail. 2017;5:471–82.
doi: 10.1016/j.jchf.2017.04.013
Ibrahim NE, Song Y, Cannon CP, Doros G, Russo P, Ponirakis A, et al. Alteration of medical therapy in patients with heart failure relative to change in symptom severity. ESC Heart Fail. 2019. https://doi.org/10.1002/ehf2.12480 .
doi: 10.1002/ehf2.12480
pubmed: 31268631
pmcid: 6816058
Emrich IE, Wintrich J, Kindermann I, Böhm M. Evidence-based drug therapy for heart failure-an update. Herz. 2019. https://doi.org/10.1007/s00059-019-4827-2 .
doi: 10.1007/s00059-019-4827-2
pubmed: 31555893
Elhmidi Y, Voss B, Lange R. Surgical mitral valve intervention following a failed MitraClip procedure. EuroIntervention. 2016;12:Y102–6.
doi: 10.4244/EIJV12SYA27
Cheng R, Dawkins S, Tat E, Makar M, Hussaini A, Makkar RR, et al. Relation of residual mitral regurgitation despite elevated mitral gradients to risk of heart failure hospitalization after mitraclip repair. Am J Cardiol. 2017;120:1595–600.
doi: 10.1016/j.amjcard.2017.07.027
Patzelt J, Zhang W, Sauter R, Mezger M, Nording H, Ulrich M Elevated mitral valve pressure gradient is predictive of long-term outcome after percutaneous edge-to-edge mitral valve repair in patients with degenerative mitral regurgitation ( MR ), But Not in Functional MR. J Am Heart Assoc. 2019 8:e011366; doi: 10.1161/JAHA.118.011366.